A Phase IB Study of Erlotinib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Previously Untreated Advanced Pancreatic Cancer.
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2016
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors OSI Pharmaceuticals
- 12 Mar 2012 Actual patient number (19) and lead trial centre added as reported by ClinicalTrials.gov.
- 12 Mar 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.
- 12 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.